The woman was accused of selling counterfeit versions of popular weight loss drugs including Ozempic and Wegovy. Experts say ...

The brand-name versions, from drugmaker Novo Nordisk, sell for around $1,000 ... tea and facial masks or hidden inside of a box of T-shirts, the spokesperson said. “The proliferation of ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

LONDON/COPENHAGEN, Dec 20 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug ...

As I'm writing these lines, Novo Nordisk A/S (NVO) is down about 16% on the pre-market session after the news came out that its obesity drug — CagriSema — delivered disappointing trial results ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.